Navigation Links
EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
Date:1/23/2013

attractive and logical treatment for sarcoma."

Ken K. Ren , Ph.D., EntreMed's Chief Executive Officer commented, "We are excited about the initiation of this trial.  We believe ENMD-2076 has good potential in the treatment of sarcoma along with other oncology indications.  In our Phase 1 trial in solid tumors, we had one patient with advanced/metastatic sarcoma relapse after multiple lines of previous therapies, however after being treated with ENMD-2076, the patient had prolonged disease PFS for 21 months.  This Phase 2 trial will enable us to explore the potential of ENMD-2076 for this indication further. We look forward to our continued advancement and development of ENMD-2076 as an oncology platform."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed, Inc. recently announced the initiation of a Phase 2 study of ENMD-2076 in triple-negative breast cancer and the initiation of a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in additi
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
2. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
3. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
4. EntreMed Reports Second Quarter 2012 Financial Results
5. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
6. EntreMed Reports First Quarter 2012 Financial Results
7. HemaTerra Announces New Quality Control Product For Blood Centers
8. Quest Announces Battery-Powered Mobile Wireless Surgical Video Display Solution
9. HOLOGIC ANNOUNCES ORGANIZATIONAL CHANGES TO ITS DIAGNOSTICS SEGMENT; INTEGRATION OF GEN-PROBE PROCEEDING AHEAD OF SCHEDULE
10. BioElectronics Announces South Korean Patent Allowance for its Innovative OTC Pain Relief Medical Devices
11. GenScript Announces Joint Road Show with Open Monoclonal Technology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Thursday, August 7, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
(Date:7/30/2014)... , July 30, 2014 PuraMed BioScience ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... M name along with the name,s red ... with the trademarked name MigraPure ®  going ... of PuraMed,s homeopathic, natural migraine pain reliever will ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... announced today that they have received CE Mark ... Velox CD™ provides a safe and predictable means ... The single size velox CD™ is indicated for ... to 8F.  Velox CD™ utilizes patented ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
(Date:7/30/2014)... July 31, 2014 “United States Orthopedic Braces ... on the United States Orthopedic Braces and Supports market. The ... (in units) and average price data (in US dollars), within ... , Ankle Braces and Supports , ... and Supports. , Orthotics is a specialty within ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nationally recognized ... CNE, ANEF, who since September 2013 has served as ... became the new dean of the College of Nursing ... move marries her leadership of the NLN, as the ... the top-ranked academic nursing and research institutions in the ...
(Date:7/30/2014)... 2014 New changes are in store for ... move to a new facility. The official date of the ... moving soon. , MedX Pharmacy will be moving into a ... 77581. This is the old Wells Fargo building. The new ... include a drive thru for convenient drop-off and pick-up of ...
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part ... most people, in 2008 he suffered extreme financial hardship and ... Paul carefully studied the difference between people who have sustainable ... on the knowledge he acquired, he was able to use ... health, but also grow his clients' personal and financial assets ...
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
Breaking Medicine News(10 mins):Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:MedX Pharmacy Relocates to New Facility 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3
... at 6th International Stem Cell Symposium Seoul, Korea - ... ... AlphaMed Press,publisher of the peer-reviewed journal STEM CELLS(R), announces that the,annual ... will be presented on June 20, 2008 in,Seoul, Korea. The US$10,000 award ...
... need, but sickest still going without, study finds , , TUESDAY, ... has resulted in some improvements for seniors but no real ... finds that Medicare beneficiaries are less likely to forego basic ... sickest patients are still skipping meds due to burdensome costs. ...
... winners from Indiana, South Carolina and Illinois are Runners-Up, ... a business niche when a friend had trouble finding ... the Year for turning his,idea into a multi-million dollar ... at the U.S. Small Business,Administration,s celebration of National Small ...
... for Policymakers, Consumers and the Media is First ... and Consumer Product,Issues, WASHINGTON, April 22 ... A Guide for,Consumers, Policymakers and the Media, the ... to provide current and scientifically accurate,information and resources ...
... greatest week after meds begin , , TUESDAY, April 22 ... are 60 percent more likely to develop pneumonia in the ... new study shows. , The risk is greatest during the ... decreases, say Dutch researchers. , "The risk of developing pneumonia ...
... Ensign,Group, Inc. (Nasdaq: ENSG ), the parent ... care services and assisted living,companies, announced today that ... results following the market close on Wednesday, May ... Conference Call, Ensign invites current and prospective ...
Cached Medicine News:Health News:Stem Cells(R) and International Stem Cell Symposium Present Annual Stem Cells(R) Young Investigator Award 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 2Health News:Online Job Search Company from Virginia is National Small Business of the Year 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 4Health News:Grocery Manufacturers Association Releases Science Policy Paper on Bisphenol A 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:The Ensign Group Schedules 2008 First Quarter Earnings Call for Thursday, May 8, 2008 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: